Next Article in Journal
The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years
Previous Article in Journal
Endothelin Blockade in Diabetic Kidney Disease
Previous Article in Special Issue
Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(6), 1193-1206;

The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases

Department of Clinical Immunology, Pathwest Laboratory Medicine, Queen Elizabeth II Medical Centre, Perth 6009, Western Australia, Australia
Department of Clinical Immunology, Royal Perth Hospital, Perth 6000, Western Australia, Australia
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain
Victor Chang Cardiac Research Institute, Sydney, 2010, New South Wales, Australia
School of Medicine and Pharmacology, Anatomy, Physiology and Human Biology, CCTRM, University of Western Australia, Perth, 6009, Western Australia, Australia
School of Medicine and Pharmacology and School of Pathology and Laboratory Medicine, The University of Western Australia, Harry Perkins Institute of Medical Research, Perth, 6009, Western Australia, Australia
Institute for Immunology and Infectious Diseases, Murdoch University, Perth, 6150, Western Australia
Author to whom correspondence should be addressed.
Academic Editor: Jane Grant-Kels
Received: 31 March 2015 / Revised: 29 April 2015 / Accepted: 11 May 2015 / Published: 28 May 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
Full-Text   |   PDF [121 KB, uploaded 28 May 2015]


The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo; and (iii) for the purposes of disease modeling in vitro. In this review, we will use examples of systemic, system-specific and organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in auto-immunity to date. View Full-Text
Keywords: inducible; pluripotent; stem cells; autoimmunity; therapy; lupus; diabetes; multiple sclerosis inducible; pluripotent; stem cells; autoimmunity; therapy; lupus; diabetes; multiple sclerosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hew, M.; O'Connor, K.; Edel, M.J.; Lucas, M. The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases. J. Clin. Med. 2015, 4, 1193-1206.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top